{"title":"致编辑的回应文章《糖格列净对2型糖尿病患者肝纤维化的影响因酒精摄入量而异》的信。","authors":"Akash Suthar, Deepa Lachhman Das","doi":"10.1111/jdi.70049","DOIUrl":null,"url":null,"abstract":"<p>Dear Editor,</p><p>To the best of our knowledge, the first study on “Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes”, penned by Mr. Ito <i>et al</i>.<span><sup>1</sup></span>, was published in your honored journal. It highlighted the favorable changes in FIB-4, HbAlc, weight loss, and serum albumin concentrations in drinkers and non-drinkers with type-2 diabetes and liver fibrosis. This retrospective study covered not only the facts respective to a topic but also the depth and diversity of the study beamed so many perspectives which enhanced our concepts. Still, there is always a margin of uncertainties and addressing those limitations will enhance the validity of further studies.</p><p>Primarily, the authors mentioned that SGLT2 therapy contributes to the prevention of cardiovascular diseases. However, the results based on drinkers and non-drinkers with or without cardiovascular diseases are lacking. Along with this.</p><p>Mr. Hajika <i>et al</i>.<span><sup>2</sup></span> also highlighted the suppression of cardiovascular diseases with luseogliflozin, such as arteriosclerosis. This restricted investigation was not able to unfold a broad aspect of this study.</p><p>Secondly, the authors highlighted the effects of luseogliflozin and its association with diabetes and liver fibrosis and its results based on FIB-4 levels. It also led to the authenticity of this study in the right direction but took the study to low accuracy, false-positive, and false-negative results, which diminishes the chance to enhance the effect of results<span><sup>3</sup></span>.</p><p>Thirdly, the study also confuses the readers with differences in FIB-4 levels in the low-risk group and intermediate-/high-risk group concerning drinkers and non-drinkers, which can be due to the hidden impact of diet on individual groups. Mr. Soleimani <i>et al</i>.<span><sup>4</sup></span> also mentioned a healthy diet pattern plays a role against hepatic fibrosis. This clarity of diet could intensify its validity and strengthen this study.</p><p>The authors declare no conflict of interest.</p><p>Approval of the research protocol: None.</p><p>Informed consent: None.</p><p>Registry and the registration no. of the study/trial: None.</p><p>Animal studies: None.</p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 6","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70049","citationCount":"0","resultStr":"{\"title\":\"Letter to the Editor in response to the article “Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes”\",\"authors\":\"Akash Suthar, Deepa Lachhman Das\",\"doi\":\"10.1111/jdi.70049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Dear Editor,</p><p>To the best of our knowledge, the first study on “Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes”, penned by Mr. Ito <i>et al</i>.<span><sup>1</sup></span>, was published in your honored journal. It highlighted the favorable changes in FIB-4, HbAlc, weight loss, and serum albumin concentrations in drinkers and non-drinkers with type-2 diabetes and liver fibrosis. This retrospective study covered not only the facts respective to a topic but also the depth and diversity of the study beamed so many perspectives which enhanced our concepts. Still, there is always a margin of uncertainties and addressing those limitations will enhance the validity of further studies.</p><p>Primarily, the authors mentioned that SGLT2 therapy contributes to the prevention of cardiovascular diseases. However, the results based on drinkers and non-drinkers with or without cardiovascular diseases are lacking. Along with this.</p><p>Mr. Hajika <i>et al</i>.<span><sup>2</sup></span> also highlighted the suppression of cardiovascular diseases with luseogliflozin, such as arteriosclerosis. This restricted investigation was not able to unfold a broad aspect of this study.</p><p>Secondly, the authors highlighted the effects of luseogliflozin and its association with diabetes and liver fibrosis and its results based on FIB-4 levels. It also led to the authenticity of this study in the right direction but took the study to low accuracy, false-positive, and false-negative results, which diminishes the chance to enhance the effect of results<span><sup>3</sup></span>.</p><p>Thirdly, the study also confuses the readers with differences in FIB-4 levels in the low-risk group and intermediate-/high-risk group concerning drinkers and non-drinkers, which can be due to the hidden impact of diet on individual groups. Mr. Soleimani <i>et al</i>.<span><sup>4</sup></span> also mentioned a healthy diet pattern plays a role against hepatic fibrosis. This clarity of diet could intensify its validity and strengthen this study.</p><p>The authors declare no conflict of interest.</p><p>Approval of the research protocol: None.</p><p>Informed consent: None.</p><p>Registry and the registration no. of the study/trial: None.</p><p>Animal studies: None.</p>\",\"PeriodicalId\":51250,\"journal\":{\"name\":\"Journal of Diabetes Investigation\",\"volume\":\"16 6\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70049\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Diabetes Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jdi.70049\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdi.70049","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Letter to the Editor in response to the article “Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes”
Dear Editor,
To the best of our knowledge, the first study on “Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes”, penned by Mr. Ito et al.1, was published in your honored journal. It highlighted the favorable changes in FIB-4, HbAlc, weight loss, and serum albumin concentrations in drinkers and non-drinkers with type-2 diabetes and liver fibrosis. This retrospective study covered not only the facts respective to a topic but also the depth and diversity of the study beamed so many perspectives which enhanced our concepts. Still, there is always a margin of uncertainties and addressing those limitations will enhance the validity of further studies.
Primarily, the authors mentioned that SGLT2 therapy contributes to the prevention of cardiovascular diseases. However, the results based on drinkers and non-drinkers with or without cardiovascular diseases are lacking. Along with this.
Mr. Hajika et al.2 also highlighted the suppression of cardiovascular diseases with luseogliflozin, such as arteriosclerosis. This restricted investigation was not able to unfold a broad aspect of this study.
Secondly, the authors highlighted the effects of luseogliflozin and its association with diabetes and liver fibrosis and its results based on FIB-4 levels. It also led to the authenticity of this study in the right direction but took the study to low accuracy, false-positive, and false-negative results, which diminishes the chance to enhance the effect of results3.
Thirdly, the study also confuses the readers with differences in FIB-4 levels in the low-risk group and intermediate-/high-risk group concerning drinkers and non-drinkers, which can be due to the hidden impact of diet on individual groups. Mr. Soleimani et al.4 also mentioned a healthy diet pattern plays a role against hepatic fibrosis. This clarity of diet could intensify its validity and strengthen this study.
The authors declare no conflict of interest.
Approval of the research protocol: None.
Informed consent: None.
Registry and the registration no. of the study/trial: None.
期刊介绍：
Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
